| REVIEW ARTICLE | Iranian Biomedical Journal 29 (5): 279-293 September 2025 |
|---|---|

# Persian Medicinal Plants as Antidiabetic Agents: Mechanisms and Evidence from Bench to Bedside

Hasan Fallah Huseini[1], Masoud Haghighi[2], Saeed Kianbakht[1] , Mojtaba Ziaee[3,4*]

[1]Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj, Iran; [2]Iranian Fisheries Science Research Institute (IFSRI), Coldwater Fishes Research Center (CFRC), Agriculture Research, Education and Extension Organization (AREEO), Tonekabon, Iran; [3]Medicinal Plants Research Center, Maragheh University of Medical Sciences, Maragheh, Iran; [4]Research Center for Integrative Medicine in Aging, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran

**OPEN ACCESS**

**Article type:** Research Article
**Received:** June 21, 2025
**Revised:** July 30, 2025
**Accepted:** August 19, 2025
**Published online:** August 20, 2025

**How to cite:**
Fallah Huseini H, Haghighi M, Kianbakht S, Ziaee M. Persian Medicinal Plants as Antidiabetic Agents: Mechanisms and Evidence from Bench to Bedside. *Iran. Biomed. J.* 2025; 29(5): 279-293.



**ABSTRACT**

The use of medicinal plants by diabetic patients dates back to ancient times. In recent years, numerous reports have been published on the efficacy and safety of many medicinal plants in the treatment of diabetes through various mechanisms. This review highlights the up-to-date proposed mechanisms of action of the most common antidiabetic herbs used in Persian medicine, comprising *Cinnamomum zeylanicum, Trigonella foenum-graecum, Urtica dioica, Nigella sativa, Citrullus colocynthis, Silybum marianum, Zingiber officinale, Punica granatum, Salvia officinalis, Vaccinium arctostaphylos, and Momordica charantia*, with support from clinical and experimental studies. Clinical research has shown significant reductions in blood glucose levels and insulin resistance, as well as improvements in diabetes-related symptoms, including digestive disorders and lipid dysregulation, accompanied by negligible adverse effects. Continuing to study how these plants work and how effectively they treat diabetes is important for using these natural treatments in modern medicine, offering affordable and safe options for diabetes patients. ***DOI: 10.61882/ibj.5073***

*Keywords:* Diabetes mellitus, Hypoglycemic agents, Persian medicinal plants, Traditional medicine

**Corresponding Author:** Mojtaba Ziaee
Medicinal Plants Research Center, Maragheh University of Medical Sciences, Maragheh, Iran; Tel.: (+98-413) 7256920-30; Mobile: (+98-914) 3131830; E-mail: ziaee@tbzmed.ac.ir; ORCID ID: 0000-0002-9725-3033

## INTRODUCTION

Medicinal plants play a significant role in the prevention and treatment of many diseases due to their popularity, low side effects, and effectiveness. Several medicinal plants have been traditionally used by diabetic patients since ancient times[1]. The efficacy and safety of self-medicating with plants in diabetic patients have drawn great attention from researchers in recent years. Interestingly, laboratory and clinical studies have demonstrated the therapeutic safety of many of these medicinal plants in the treatment of diabetes[2]. In this regard, due to the complexity and multifactorial nature of diabetes, as well as the multifaceted effects of medicinal plants, various mechanisms can be involved in the effectiveness of medicinal plants on diabetes[3]. Medicinal plants, as natural products, have numerous biological and medicinal properties, including preventive and therapeutic effects on diabetes through various cellular and molecular mechanisms[3,4]. The aim of this study was to review the mechanisms of antidiabetic effects of medicinal plants used in traditional Persian medicine, whose effectiveness has been confirmed in clinical studies.

### *Cinnamomum zeylanicum* L. (Cinnamon)

Cinnamon is a common spice with antidiabetic properties in many traditional medicines. Its antidiabetic effect has been proven in laboratory and clinical studies[5,6]. The major cinnamon chemical components are eugenol, cinnamaldehyde, camphor, cinnamyl acetate, and copane, along with other minor constituents[7]. The hypoglycemic effect of cinnamon may be due to its multiple mechanisms of action. Cinnamaldehyde, one of the main chemical components



[ DOI: 10.61882/ibj.5073 ]

of cinnamon, has antidiabetic effects by regulating glucose and blood lipids, improving insulin resistance, and promoting antioxidant activity[8]. Eugenol, another cinnamon chemical component, potentiates insulin sensitivity and promotes skeletal muscle glucose uptake in diabetic rats in addition to its anti-inflammatory and antioxidant effects[9]. It has been reported that the phytochemical composition in cinnamon facilitates the glucose entry into cells by interacting with the insulin receptor[10]. Cinnamon also increases the sensitivity of cells to insulin and stimulates cellular glucose uptake[11]. The antioxidant effects of cinnamon protect pancreatic β-cells from oxidative stress damage, and its anti-inflammatory effects have been beneficial in diabetes[12,13]. Another possible antidiabetic mechanism includes an inhibitory effect on intestinal β-glucosidase and pancreatic amylase[14] and also the ability of this plant to delay gastric emptying after meals[15]. Furthermore, it has been reported that the antidiabetic effects of cinnamaldehyde may be due to its enhancement of intestinal barrier integrity, amelioration of inflammatory responses, and remodeling of the gut microbiome[16,17].

### *Trigonella foenum-graecum* L. (Fenugreek)

Fenugreek has been widely used around the world for dietary cooking purposes and also as a component in varying herbal formulations in Persian medicine for the treatment of several ailments, including diabetes, hyperlipidemia, and obesity[18,19]. Fenugreek's pharmacological effects are attributed to its bioactive compounds, such as polyphenols, steroids, lipids, alkaloids, saponins, flavonoids, hydrocarbons, carbohydrates, galactomannan fiber, and amino acids[20]. Trigonelline, 4-hydroxyisoleucine, and diosgenin are considered the most bioactive substances of fenugreek with antidiabetic activity[21]. Several experimental and clinical trials have shown that fenugreek seeds can improve most metabolic symptoms associated with both type 1 and type 2 diabetes in animals and humans[22,23] In a systematic review study including 43 trials with 2,334 participants, the beneficial effects of fenugreek seed consumption on glycemic control and metabolic syndrome have been documented[24]. Multiple mechanisms have been proposed to explain the metabolic and antidiabetic effects of fenugreek and its components**.** Clinical evidence indicates that its consumption improves glycemic control primarily by enhancing insulin sensitivity and reducing insulin resistance[25,26]. Other studies have reported that consuming fenugreek can increase insulin secretion through the direct effects of Langerhans cells or by reducing oxidative stress on beta cells to restore their function[27], and improve glucose absorption in the peripheral tissues by directly targeting adipose tissue[28]. In an in vitro study, fenugreek leaf extract inhibited α-amylase and α-glucosidase activity[29]. In addition, the high fiber content of fenugreek seeds has delayed effects on carbohydrate digestion due to prolonged gastric emptying time, which reduces glucose absorption in the small intestine[30]. Furthermore, the significant reversed dysbiotic effect of fenugreek on gut microbiota is correlated with overall glucose metabolism and its hypoglycemic action[31].

### *Urtica dioica* L. (Nettle)

Globally, traditional medicine uses nettle to treat various ailments. In Persian medicine, nettle leaf distillate has been widely used as an antihyperglycemic agent[32]. The plant root and aerial part contain many phytochemical compounds, such as phenolic compounds, sterols, fatty acids, alkaloids, terpenoids, flavonoids, and lignans[33]. The nettle's hypoglycemic effects have been reported in several studies. In an experimental animal study, treatment of diabetic rats with aqueous extract of nettle leaves showed a strong glucose-lowering effect[34]. The antihyperglycemic effects have also been confirmed in several clinical trials. In a three-month randomized, double-blind, placebo-controlled clinical trial, 1,500 mg of nettle leaf extract improved glycemic control in patients with advanced type 2 diabetes[35]. In another two clinical trials, significant decreases in insulin resistance indices were reported in type 2 diabetic patients treated with nettle leaf extract[36,37]. Furthermore, a 90-day clinical trial study indicated the antihyperglycemic effects of an herbal formulation containing a mixture of *Boswellia serrata* resin, *Silybum marianum* seeds, and nettle leaf extract[38]. The proposed mechanism for nettle hypoglycemic effects may be due to promising α-amylase and β-glucosidase inhibition[39], enhanced glucose uptake by skeletal muscles and adipose tissues[40], enhanced glucose uptake by creating glucose-permeable pores[41], decreased insulin resistance, and increased insulin secretion by Langerhans islets[42,43], augmented GluT2 gene expression[44], and regeneration of pancreatic beta cells[45]. Nettle contains several antioxidant components, making it an effective approach to controlling diabetes and reducing associated complications[46]. The effects on gut microbiota composition and alterations in amino acid metabolism by nettle may also contribute to the mechanisms by which nettle improves metabolic health[47].

### *Nigella sativa* L. (black seed)

Black seed is widely used for its culinary and medicinal properties, especially in North Africa, the



[ DOI: 10.61882/ibj.5073 ]

Middle East, Europe, and Asian countries. The seeds and their oil also have a long history of use in traditional medicine in almost all countries to treat a variety of ailments, including obesity and diabetes[48]. Many active compounds, including thymoquinone, thymohydroquinone, dithymoquinone, p-cymene, carvacrol, α-pinene, thymol, niglycymine, and niglycine, have been identified in black seed. These compounds are responsible for many pharmacological effects of black seed, including antidiabetic, anti-inflammatory, antioxidant, and immunomodulatory properties, which have been published in various studies[49]. Numerous laboratory and clinical studies have confirmed its antidiabetic effect. In experimental studies, the administration of an aqueous extract of black seed or its oil improved blood insulin levels, hyperglycemia, and lipid profiles[50]. In two clinical trial studies, hypoglycemic and metabolic benefits were observed in type 2 diabetic patients taking 2.5 ml of black seed oil twice daily for three months[51]. In two other clinical trial studies, antidiabetic effects were reported in patients taking 500 mg and 2 g of black seed powder daily for two months[52] and 12 weeks, respectively[53]. Researchers have proposed various mechanisms for the antidiabetic activity of black seed. In experimental and clinical studies, black seed improves insulin secretion and hepatic glycogen storage[54], prevents β-cell damage[55], inhibits α-glucosidase and α-amylase enzyme activity[56], reduces the body's inflammatory and oxidative stress markers[57], increases pancreatic islet cell regeneration[58], inhibits intestinal glucose absorption[59], increases glucose uptake in skeletal muscles[60], and modulates the disturbed gut microbiota[61].

### *Citrullus colocynthis* L. (Colocynth)

In Persian medicine, colocynth is used to treat several ailments, including diabetes and digestive disorders such as indigestion, constipation, and intestinal paralysis[62]. Colocynth is a source of several bioactive compounds, such as cucurbitacin, essential oils, glycosides, saponins, flavonoids, polyphenols, alkaloids, and fatty acids[63]. It exhibits several pharmacological properties, including antidiabetic, antioxidant, and anti-inflammatory effects, as well as powerful laxative and purgative effects[64]. Its hypoglycemic effect has been reported in experimental and clinical trials[65,66]. Although the exact hypoglycemic mechanism of colocynth is unclear, it has been reported that its fruit and seed extracts have an insulinotropic effect in an experimental study[67]. In an in vitro study, the hydrolysates from colocynth seed-derived proteins effectively inhibited α-glucosidase and α-amylase activity[68]. The antioxidant and anti-inflammatory effects of colocynth may play a role in restoring metabolic defects in diabetic patients[69-71]. Chronic constipation is one of the most common digestive complications of diabetic patients[72]. Colocynth has laxative and purgative properties, which may benefit diabetic patients by relieving constipation and improving digestive function[62].

### *Silybum Marianum* L. (Milk thistle)

Milk thistle seeds have been used for centuries as an herbal medicine for various diseases, especially liver and bile problems[73]. In recent years, its seed extract has been promoted as a dietary supplement for hepatitis, cirrhosis, jaundice, diabetes, indigestion, and other conditions[74]. The Milk thistle seed extract (silymarin) contains many active constituents, including several flavonolignans, namely silibinin A, silibinin B, isosilibinin A, isosilibinin B, silychristin, and silydianin[75]. In experimental studies, the hypoglycemic effects of silymarin have been reported in different diabetic animal models[76]. Apart from experimental studies, improved hyperglycemia has been reported with a daily dose of 600 mg of silymarin in three clinical trials, including type 2 diabetic patients, type 2 diabetic patients who are candidates for insulin therapy, and first-degree relatives of type 2 diabetic patients[77-79]. The antidiabetic properties of silymarin are mediated through multiple mechanisms. These mechanisms include ameliorating insulin resistance and enhancing its secretion[80], protecting pancreatic β-cells from oxidative stress-mediated destruction[81], promoting their proliferation[82], impairing carbohydrate digestion by inhibiting α-amylase and α-glucosidase activities[83], suppressing inflammatory pathways and oxidative stress[84], regulating hepatic glucose output via the gut-brain-liver axis[85], and modulating the composition of the gut microbiota[86].

### *Zingiber officinale* L. (Ginger)

Ginger, a most widely consumed spice worldwide, has a long history of use as an herbal medicine to treat a variety of diseases, including nausea and vomiting, constipation, indigestion (dyspepsia), pain, and cold syndromes[87]. Ginger is rich in various chemical constituents, containing phenolic compounds, terpenes, polysaccharides, lipids, organic acids, and raw fibers. The phenolic compounds are mainly gingerols, shogaols, and paradols, which are responsible for most of the bioactivities of ginger[88]. Accumulating studies have demonstrated that ginger has the potential to prevent and manage several diseases, including diabetes mellitus. In a systematic review and meta-analysis of eight randomized trials consisting of a total number of



[ DOI: 10.61882/ibj.5073 ]

454 participants who underwent ginger therapy (1600-4000 mg daily), glycosylated hemoglobin levels were significantly improved, showing that this natural medicine may have an impact on glucose control in patients with type 2 diabetes[89]. The antidiabetic mechanism of ginger may be due to enhanced insulin secretion from pancreatic β-cells[90], decreased insulin resistance[91], increased glucose-stimulated insulin secretion pathway in pancreatic beta cells[92], and enhanced insulin-stimulated glucose uptake in peripheral insulin-responsive adipocytes[93]. The inhibitory potential of ginger extracts against enzymes is linked to type 2 diabetes, inflammation, and induced oxidative stress[94]. The antioxidant and anti-inflammatory effects of ginger also have the potential to prevent and reduce diabetic complications[95]. In addition, ginger improves the overall structure of intestinal microbiota by enriching effective bacteria such as Faecalibacterium and Blautia[96], with a positive impact on intestinal integrity and mitochondrial dysfunction. Furthermore, it improves glucose metabolism in the digestive system[97].

***Punica granatum* L**. (**Pomegranate**)

In Persian medicine, the pomegranate is known to tonify the stomach and liver and prevent bleeding, as well as heal wounds. The different parts of plants, such as flowers, fruits, stems, leaves, and roots, have antioxidant, antidiabetic, antihyperlipidemic, anti-inflammatory, anticarcinogenic, antimicrobial, and antidiarrheal properties[98]. So far, many phytochemicals have been identified in pomegranate. Anthocyanins in the seeds, along with flavonoids and hydrolysable tannins (such as gallotannins, ellagitannins, punicalgin, and punicalin) found in the leaves, bark, and fruits, are responsible for the potential health benefits of pomegranate[99]. The hypoglycemic effects of pomegranate leaves, flowers, peels, and juice have been reported in several experimental and clinical studies[100]. In a clinical trial, administration of 50 g of pomegranate juice per day to type 2 diabetic patients for three months reduced glucose level, total cholesterol, and LDL cholesterol content[101]. Multiple mechanisms of action have been proposed for the hypoglycemic effect of different parts of pomegranate. In clinical studies, the consumption of pomegranate seed juice has been shown to suppress reactive oxygen, reduce insulin resistance, and enhance β-cell function[102,103]. Pomegranate flower extract contains a large number of polyphenols with potent anti-inflammatory and antioxidant effects[104,105]. In an experimental study, the improvement of insulin sensitivity and inhibition of α-glucosidase activity were reported in diabetic rats treated with pomegranate flower extract[106,107]. Furthermore, it has been reported that the antidiabetic effects of pomegranate flowers may be due to their prebiotic and stimulatory effects on gut bacteria growth[108].

***Salvia officinalis* L. (Sage)**

Sage has a long history in medicinal and culinary uses. It has been utilized in folk medicine for its digestive, carminative, antispasmodic, sedative, analgesic, tonic, and diuretic properties, as well as for the treatment of functional gastrointestinal disorders, since ancient times[109]. Sage essential oil contains a large number of chemical constituents, which consist of borneol, camphor, caryophyllene, cineole, elemene, humulene, ledene, and pinene, while its extract contains phenolic compounds, alkaloids, and waxes[110]. Sage is claimed to be beneficial for diabetic patients, and several experimental studies and clinical trials have confirmed its hypoglycemic effects[111]. In experimental studies, the blood sugar-lowering effects of sage extract and its essential oil have been reported in both healthy and diabetic rats[112]. The antidiabetic effect of sage was also confirmed in clinical trials. In a two-month clinical trial study, the effect of daily administration of 1500 mg of sage on lowering blood sugar and blood lipids in type 2 diabetic patients was reported[113]. Researchers have proposed a few mechanisms for the hypoglycemic effects of sage. In a laboratory study, the inhibitory effects of sage on intestinal glucose absorption were suggested to be due to its α-amylase and α-glucosidase inhibitory properties[114]. Another laboratory study found that sage essential oil inhibited gluconeogenesis and enhanced the sensitivity of liver cells to insulin. In the same study, sage decoction increased glucose uptake capacity and decreased gluconeogenesis in cultured hepatocytes in response to glucagon[115]. The anti-inflammatory and antioxidant effects of sage are also involved in metabolic abnormalities due to its hyperglycemic property[116]. Furthermore, a study on adipocyte cells found that sage extract increased insulin sensitivity and decreased lipogenesis[117]. Sage also modulates the gut microbiota, which may support a healthier gut microbiome and improve glucose metabolism[118].

***Vaccinium arctostaphylos* L. (Caucasian whortleberry)**

Caucasian whortleberry leaves and fruits have long been used by traditional medicine healers to treat blood sugar, blood pressure, fever, along with bladder and urinary tract diseases[19]. Many compounds, such as polyphenols and anthocyanins, including delphinidin 3-O-β-glucoside, petunidin 3-O-β-glucoside, and malvidin 3-O-β-glucoside, have been identified in the leaves and fruits of this plant[119]. The findings of



[ DOI: 10.61882/ibj.5073 ]

experimental and clinical studies have shown that the fruit and leaves of Caucasian whortleberry have antidiabetic effects. In a study on living animals, administering Caucasian whortleberry fruit extract to diabetic rats resulted in lower blood sugar and fat levels after eating[119]. In a clinical trial, diabetes improvement was reported in type 2 diabetic patients who were resistant to conventional oral antihyperglycemic drugs following the administration of a Caucasian whortleberry fruit extract[120]. Another study reported that administering Caucasian whortleberry leaf extract to diabetic patients with high blood pressure had antiglycemic and lipid-lowering effects[121]. In this regard, fasting blood glucose, two-hour postprandial glucose, and insulin resistance were also significantly reduced in diabetic patients treated with Caucasian whortleberry[122]. Since few studies have been performed on this plant, the published mechanisms of its antidiabetic effects remain limited. In an experimental study, the administration of Caucasian whortleberry fruit extract to diabetic rats increased the activity of hepatic glucokinase, glucose-6-phosphate dehydrogenase, and glycogen concentration[123]. In another experimental study, it was suggested that Caucasian whortleberries blood sugar, likely through blocking α-glucosidase in the intestine, boosting glucose transporter protein in muscle tissues, and increasing the expression of insulin genes in the pancreas[124]. The glucose transporter protein is a protein that enhances insulin-regulated glucose uptake into muscle and fat cells[125]. Other studies have reported that the antidiabetic effects of Caucasian whortleberry may be due to its antioxidant, α-glucosidase inhibitory, anti-inflammatory, and DNA protective properties[126,127].

***Momordica charantia* L. (karela)**

Apart from the use of karela in various types of Asian cuisine, its fruit has a long history in the traditional medicine of many countries[128]. Numerous studies have reported that karela fruit contains various chemical compounds, including saponins, polypeptides, flavonoids, alkaloids, polysaccharides, and sterols, which are responsible for the antioxidant, antidiabetic, hepatoprotective, anti-inflammatory, and immuno-modulatory activities[128]. Over the past several years, a large number of scientific studies, including experimental and clinical trials, have investigated the antidiabetic effects of karela fruit[129]. In an experimental study, the hypoglycemic effect of a polysaccharide isolated from karela fruit was reported when administered to diabetic mice[130]. In a clinical trial, the blood sugar-lowering effects of karela were observed in type 2 diabetic patients when its fruit extracts were administered[131]. Several mechanisms for its antidiabetic effect have been documented. As reported in diabetic patients, karela exerted hypoglycemic effects by stimulating insulin secretion[131]. In experimental studies, karela has been shown to improve insulin resistance[132], increase glucose uptake and glucose clearance through the activation of the insulin receptor signaling pathway[133], protect pancreatic cell damage[134], and inhibits α-amylase activity[135]. In addition, karela, due to its strong antioxidant and anti-inflammatory activities, improves lipid and glucose metabolism and insulin function by inhibiting inflammatory cytokines in fat tissues[136]. Karela also affects glucose absorption by improving gut metabolic disorders and microbiota defects[137].

## DISCUSSION

The body maintains blood sugar homeostasis through an integrated series of processes. These processes include intestinal glucose absorption, pancreatic insulin secretion triggered by rising glucose levels, cellular glucose uptake, and the storage and release of glucose by the liver[138,139]. Any defect in these pathways can disrupt glucose metabolism, leading to increased blood sugar levels. Herbal medicines may affect one or more positions in the pathways of glucose absorption and metabolism. In this light, numerous laboratory and clinical studies have been conducted to find out the mechanism of action of antidiabetic herbal medicines in the body. In the current study, the antidiabetic mechanisms of commonly used medicinal plants, including *Cinnamomum zeylanicum, Trigonella foenum-graecum, Urtica dioica, Nigella sativa, Citrullus colocynthis, Silybum marianum, Zingiber officinale, Punica granatum, Salvia officinalis, Vaccinium arctostaphylos, and Momordica charantia*, were investigated. These plants contain many active compounds with a specific mechanism of action that can exert therapeutic effects in diabetic patients by improving body disorders[140].

One important mechanism of action reported by all the above-mentioned plants is the improvement of insulin action (Table 1). This effect was due to the improvement of body cells' sensitivity to insulin and the increase in insulin secretion caused by these plants. Impaired insulin secretion and insulin resistance are key pathophysiological features of type 2 diabetes. This condition leads to a reduced response to insulin in muscle, liver, and adipose tissue, subsequently decreasing glucose uptake into these cells[141]. Many of the existing synthetic antidiabetic drugs used in the treatment of type 2 diabetes lower blood sugar by affecting insulin activity or insulin release[142].



[ DOI: 10.61882/ibj.5073 ]

**Table 1.** Studies conducted to evaluate the mechanism of action of antidiabetic herbal medicines

| Sr. No. | Herbal medicine | Proposed mechanism of action | Compound/test design | References |
|---|---|---|---|---|
| 1 | *Cinnamomum zeylanicum* | Improving insulin resistance | Cinnamaldehyde/db-db mice | [8] |
| | | Improving SMGU; reducing OX; decreasing inflammation | Eugenol/DM rat | [9] |
| | | Increasing CGU; exerting anti-inflammatory effects | AQ extract/3T3-L1 adipocytes | [10] |
| | | Improving insulin sensitivity | Cinnamon/(HF/HF) fed rat | [11] |
| | | Improving β-cell function; protecting from OX | EA fraction/β cell lines | [12] |
| | | Exerting anti-inflammatory effects, inhibiting OX | Cinnamon extract/DM patient | [13] |
| | | Inhibiting intestinal β-glucosidase and PA | DS extract/enzymatic | [14] |
| | | Slowing gastric emptying | Cinnamon/healthy subjects | [15] |
| | | Enhancing IBI; remodeling GM | Cinnamaldehyde/rats | [16] |
| | | Changing gut microbiota | Cinnamon/diabetic patients | [17] |
| 2 | *Trigonella foenum-graecum* (fenugreek) | Improving insulin resistance | Fenugreek/DM patient | [25] |
| | | Improving insulin sensitivity | Fenugreek seeds/healthy subject | [26] |
| | | Stimulating glucose-induced insulin release | 4-HIL/rat and human β-cell | [27] |
| | | Reducing OX and PPARγ activity | DG and TIRG/ rat pancreas/AT | [28] |
| | | Improving inflammation and glucose metabolism | Fenugreek/KK-Ay HFD mice AT | [29] |
| | | Inhibiting α-amylase and β-glucosidase | AQ leaves extracts/enzymatic | [30] |
| | | Inhibiting glucose absorption due to PGET | Fenugreek SDFF/DM rat SI | [31] |
| | | Reversing dysbiotic effects on gut microbiota | Fenugreek/HFD mice | [32] |
| 3 | *Urtica dioica* (nettle) | Inhibiting α-amylase and β-glucosidase | UD extract/enzymatic | [39] |
| | | Enhancing glucose uptake | UD decoction/rat SM and AT | [40] |
| | | Decreasing insulin resistance | UD decoction/C57BL/6J mice | [42] |
| | | Enhancing insulin secretion | UD extracts/rat β-cells | [43] |
| | | Increasing GLUT2 gene expression in the liver | UD distillate/DM mice liver cells | [44] |
| | | Regenerating pancreatic beta cells | UD distillate/DM rats | [45] |
| | | Exerting antioxidant properties | UD extracts/laboratory | [46] |
| | | Altering gut microbiota composition | UD extracts/obese mice | [47] |
| 4 | *Nigella sativa* L. | Improving insulin secretion, HG storage, and OS | TQ/DM rats | [54] |
| | | Preventing β-cell damage | Volatile oil/DM rats | [55] |
| | | Inhibiting α -glucosidase and α-amylase EA | NS extract/in vitro | [56] |
| | | Reducing inflammation and OS markers | NS oil/RA patient | [57] |
| | | Increasing pancreatic islet cell regeneration | Volatile oil/DM rats | [58] |
| | | Inhibiting intestinal glucose absorption | NS AQ extract/in vitro | [59] |
| | | Increasing GU in muscle cells and adipocytes | NS extract/cell line | [60] |
| | | Restorating disturbed gut microbiota | NS oil/rat | [61] |
| 5 | *Citrullus colocynthis* | Exerting insulinotropic action | Fruit extracts/rat pancreatic islets | [67] |
| | | Inhibiting α-glucosidase and α-amylase | Colocynth seed protein/enzymatic | [68] |
| | | Preventing glucose toxicity | Fruit extract/ PC-12 cells | [69] |
| | | Reducing of oxidative stress | Fruit extract/diabetic patient | [70] |
| | | Reducing oxidative stress and inflammation | Fruit extract/rat liver damage | [71] |
| | | Improving constipation and digestive function | Fruit powder/diabetic patient | [62] |
| 6 | *Silybum marianum* | Improving insulin resistance | Silymarin/F-DR of DM patient | [78] |
| | | Stimulating insulin secretion | Silymarin/β-cell line | [80] |
| | | Inhibiting OX-mediated destruction of $\beta$ cells | Silymarin/invitro in rats | [81] |
| | | Proliferating insulin-producing cells | Silymarin/AI-DM rats | [82] |
| | | Inhibiting α-amylase and α-glucosidases | Silymarin/enzymatic | [83] |
| | | Downregulating inflammation and OX | Silymarin/diabetic patient | [84] |
| | | Decreasing HGP by triggering the GBLA | Silibinin/DM rats | [85] |
| | | Modulating fecal microbiota composition | Silymarin/sows fecal microbes | [86] |



[ DOI: 10.61882/ibj.5073 ]

| Sr. No. | Herbal medicine | Proposed mechanism of action | Compound/test design | References |
|---|---|---|---|---|
| 7 | *Zingiber officinale (Ginger)* | Enhancing β-cells' insulin secretion | Steamed ginger/pancreatic β-cells | [90] |
| | | Improving insulin resistance | Ginger/DM patient | [91] |
| | | Improving GSIS in pancreatic β-cells | Gingerol/db/db DM mice β-cells | [92] |
| | | Increasing ISGU in peripheral adipocytes | Ginger/adipocytes cell line | [93] |
| | | Inhibiting α-amylase and α-glucosidases | Ginger extracts/enzymatic | [94] |
| | | Exerting antioxidative and anti-inflammatory effects | Ginger/Diabetic rats | [95] |
| | | Changing intestinal flora | Ginger Juice/healthy adults | [96] |
| | | Improving intestinal mitochondrial function | Ginger/Diabetic rats | [97] |
| 8 | *Punica granatum* L. | Exerting antioxidant effects | Seed juice/ athletes | [102] |
| | | Improving insulin resistance and *β*-cell function | Seed juice/DM patient | [103] |
| | | Exerting anti-inflammatory effects | Flower extract/DM rats | [104] |
| | | Exerting antioxidant effects | Flower extract/MCL | [105] |
| | | Improving insulin sensitivity | Flower extract/DPPH assay | [106] |
| | | Inhibiting α-glucosidase activity | Flower extract/DM rats/in vitro | [107] |
| | | Stimulating gut bacteria growth | Flower extract/in vitro | [108] |
| 9 | *Salvia officinalis* L. | Inhibiting α-amylase and α-glucosidase | Sage extract/enzymatic | [114] |
| | | Improving insulin sensitivity and inhibiting GNG | Sage EO/rat hepatocyte | [115] |
| | | Increasing HGUC and inhibiting GNG | Sage decoction/rat hepatocyte | [115] |
| | | Exerting anti-inflammatory and antioxidant effects | Sage extract/inflammation in rat | [116] |
| | | Improving insulin resistance | Sage extract/HFD-IO in mice | [117] |
| | | Modulating gut microbiota | Sage extract/sea bass | [118] |
| 10 | *Vaccinium arctostaphylos* L. | Increasing hepatic glycogen, GK, and G6PD | VA fruit extract/ DM rats | [123] |
| | | Increasing serum insulin and adiponectin levels | VA fruit extract/ DM rats | [124] |
| | | Inhibiting α-glucosidase activity in the intestine | VA fruit extract/ enzymatic | [124] |
| | | Uptaking insulin-regulated glucose into cells | VA fruit extract/ enzymatic | [125] |
| | | Decreasing oxidative stress | VA fruit extract / DM patients | [126] |
| | | Exerting anti-inflammatory and DNA protective effects; inhibiting α-glucosidase | VA fruit extract/ enzymatic | [127] |
| 11 | *Momordica charantia* L. | Increasing insulin levels | MC extract/DM patient | [131] |
| | | Improving insulin resistance | MC extract/HFDF mice | [132] |
| | | Improving glucose uptake and glucose clearance | MC-IRBP/DM mice | [133] |
| | | Protecting damage to pancreatic cells | MC polysaccharide/DM mice | [134] |
| | | Inhibiting α-amylase | MC polysaccharide/enzymatic | [135] |
| | | Exerting antioxidant activity | MC polysaccharide/laboratory | [136] |
| | | Stimulating peripheral and skeletal muscle glucose utilization; modulating intestinal microbiota disorders | FMC polysaccharide/obese rats | [137] |

SMGU: skeletal muscle glucose uptake; OX: oxidative stress; CGU: cellular glucose uptake; PA: pancreatic amylase; IBI: intestinal barrier integrity; db-db: leptin receptor-deficient diabetes; HF/HF: high fat/high fructose; EA: ethyl-acetate; CRP: C-reactive protein; DS: distilled water; GM: gut microbiome; CD: carbohydrate digestion; PPARγ: peroxisome proliferator-activated receptor-gamma; PGET: prolonged gastric emptying time; TIRG: trigonelline; DG: diosgenin; 4-HIL: 4-hydroxyisoleucine; HFD: high fat diet; AT: adipose tissue; AQ: aqueous; SDFF: soluble dietary fiber fraction; DM: diabetic; SI: small intestine; GLUT2: glucose transporter 2; UD: *urtica dioica*; SM: skeletal muscle; HG: hepatic glycogen; EA: enzyme activity; GU: glucose uptake; TQ: thymoquinone; NS: *nigella sativa*; RA: rheumatoid arthritis; PC12: cell line derived from a pheochromocytoma of the rat adrenal medulla; F-DR: first-degree relatives; HGP: hepatic glucose production; GBLA: gut-brain-liver axis; AI: alloxan induced; EXP: experimental; GSIS: glucose-stimulated insulin secretion; ISGU: insulin stimulated glucose uptake; MCL: macrophages cell line; DPPH: 2,2-diphenyl-1-picrylhydrazy; HGUC: hepatocyte glucose uptake capacity; GNG: gluconeogenesis; HFD-IO: high fat diet-induced obesity; EO: essential oil; LPS: lipopolysaccharide; GK: glucokinase; G6PD: glucose-6-phosphate dehydrogenase; VA: *Vaccinium Arctostaphylos*; PIGE: pancreatic insulin genes expression; GH: glucose homeostasis; HFDF: high-fat-diet; MC: momordica charantia; MC-IRBP: momordica charantia insulin receptor-binding protein; TTP: triterpenoids; FMC: fermented momordica charantia;



[ DOI: 10.61882/ibj.5073 ]

Inhibition of intestinal α-amylase and α-glucosidase activity was another important mechanism of the antidiabetic effects reported by these plants (Table 1). Intestinal α-amylase and α-glucosidase enzymes help break down carbohydrates into simple sugars, which allows glucose to be absorbed from the digestive tract. Their inhibition can significantly prevent the increase in blood sugar levels after a meal. Therefore, this therapeutic effect can be an important strategy in managing blood sugar levels in type 2 diabetic patients[143]. In addition, antioxidative and/or anti-inflammatory effects have also been reported by all the mentioned plants (Table 1). Although the direct relationship between oxidation and diabetes has not been established, it is claimed that increased oxidation contributes to insulin resistance and impaired secretion. The antidiabetic benefits of dietary antioxidants may be attributed to the regulation of insulin secretion, increased insulin sensitivity, and improved glucose metabolism[144]. For instance, in a clinical trial study, applying vitamin E improved insulin-mediated glucose uptake[145]. Chronic inflammation can be a complication of diabetes and also a risk factor for diabetes by increasing insulin resistance. In this regard, it has been determined that the antidiabetic effects of sitagliptin, a synthetic antidiabetic drug, are due to its anti-inflammatory properties, which improve insulin secretion and function[146]. Another important antidiabetic mechanism reported for most of the above plants is their influence on gut microbiota (Table 1). Alteration of the gut microbiota is an important factor associated with the development of type 2 diabetes and its complications[147]. It has been reported that decreased glucose tolerance and insulin resistance, which occur with the onset of obesity, metabolic syndrome, and type 2 diabetes, are associated with disruption of the gut microbiota[148]. However, a promising new approach to diabetes treatment has focused on modulating the gut microbiota with prebiotics and synbiotics[149]. In this regard, research has shown that one of the antidiabetic mechanisms of metformin, a widely used antidiabetic drug, is the regulation of intestinal microbiota[150].

Given the complex nature of diabetes and the diverse compounds in medicinal plants, future research should extend beyond the mechanisms discussed in this review. Key priorities include isolating bioactive compounds, standardizing extracts, and employing nanoformulations to improve bioavailability. Furthermore, in-depth mechanistic studies on insulin signaling, glucose metabolism, and gut-microbiota interactions are essential to elucidate their multi-target actions. Finally, rigorous clinical trials—focusing on dosage, safety, and potential herb-drug interactions—are crucial for validating efficacy and ensuring patient safety in insulin-resistant populations.

## CONCLUSION

The findings of this review demonstrate that the antidiabetic effects of medicinal plants are mediated through multiple mechanisms, including enhancing insulin secretion, improving insulin sensitivity, promoting peripheral glucose uptake, inhibiting intestinal glucose absorption, and modulating gut microbiota. This diverse range of pharmacological actions offers fresh ideas for innovative diabetes treatment strategies, allowing for the selection and combination of medicinal plants based on their mechanisms of action. Although several medicinal plants have shown clinically significant glycemic control, first-line antidiabetic drugs such as metformin remain superior for long-term monotherapy due to their well-established efficacy, extensive safety profile, and demonstrated cardiovascular benefits. Medicinal plants are most appropriately used as adjunctive therapy rather than replacements for conventional drugs, particularly in advanced diabetes. Some botanical preparations may exhibit synergistic effects when combined with antidiabetic medications, potentially allowing for dose reduction and decreased side effects. There are several important safety considerations when using medicinal plants, including the lack of adequate safety data for medicinal plants in vulnerable populations, such as pregnant women, children, and elderly patients. In contrast, conventional antidiabetic drugs have well-documented safety profiles in these groups. Although medicinal plants show promise for managing prediabetes or as complementary therapies, they require rigorous long-term studies, product standardization, and increased safety monitoring before they can be considered real alternatives to conventional treatments. Finally, despite significant research in recent decades on antidiabetic medicinal plants demonstrating their effectiveness, there is undoubtedly a need for laboratory research and long-term clinical trials with an appropriate design to accurately determine their efficacy, safety, action mechanisms, and optimal dosing protocols.

## DECLARATIONS

**Acknowledgments**

During the preparation of this work, the authors utilized QuillBot to fix grammar mistakes and make the language clearer and coherent. The authors carefully examined and revised the content after utilizing this tool or service. They wholeheartedly accept responsibility for the publication's content.



[ DOI: 10.61882/ibj.5073 ]

**Ethical approval**
Not applicable.

**Consent to participate**
Not applicable.

**Consent for publication**
All authors reviewed the results and approved the final version of the manuscript.

**Authors' contributions**
HFH: conceptualization, methodology, investigation, resources, data curation, writing–original draft, and project administration; MH: methodology, validation, formal analysis, data curation, writing–review and editing; SK: conceptualization, investigation, writing–review & editing; MZ: conceptualization, supervision, methodology, investigation, writing–original draft, writing–review & editing.

**Data availability**
All relevant data can be found within the manuscript.

**Competing interests**
The authors declare that they have no conflict of interest.

**Funding**
This research received no specific grant from any funding agency in the public, commercial. or not-for-profit sectors.

**Supplementary information**
The online version does not contain supplementary material.

## REFERENCES

1. Farzaei F, Morovati MR, Farjadmand F, Farzaei MH. A mechanistic review on medicinal plants used for diabetes mellitus in traditional Persian medicine. Journal of evidence-based complementary & alternative medicine. 2017;22(4):944-55.
2. Kumar S, Mittal A, Babu D, Mittal A. Herbal medicines for diabetes management and its secondary complications. Current diabetes reviews. 2021;17(4):437-56.
3. Balbaa M, El-Zeftawy M, Abdulmalek SA. Therapeutic screening of herbal remedies for the management of diabetes. Molecules. 2021;26(22):6836.
4. Alam S, Sarker MMR, Sultana TN, Chowdhury MNR, Rashid MA, Chaity NI, et al. Antidiabetic phytochemicals from medicinal plants: prospective candidates for new drug discovery and development. Frontiers in endocrinology. 2022;13:800714.
5. Rekha N, Balaji R, Deecaraman M. Antihyperglycemic and antihyperlipidemic effects of extracts of the pulp of Syzygium cumini and bark of Cinnamon zeylanicum in streptozotocin-induced diabetic rats. J Appl Biosci. 2010;28(1):1718-30.
6. Zahmatkesh M, Fallah Huseini H, Hajiaghaee R, Heidari M, Mehrafarin A, Tavakoli-Far B. The effects of Cinnamomum zeylanicum J. Presl on blood glucose level in patients with type 2 diabetes, a double-blind clinical trial. Journal of Medicinal Plants. 2012;11(41):258-63.
7. Alizadeh Behbahani B, Falah F, Lavi Arab F, Vasiee M, Tabatabaee Yazdi F. Chemical composition and antioxidant, antimicrobial, and antiproliferative activities of Cinnamomum zeylanicum bark essential oil. Evidence-based complementary and alternative medicine. 2020;2020.
8. Guo X, Sun W, Huang L, Wu L, Hou Y, Qin L, et al. Effect of cinnamaldehyde on glucose metabolism and vessel function. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. 2017;23:3844.
9. Al-Trad B, Alkhateeb H, Alsmadi W, Al-Zoubi M. Eugenol ameliorates insulin resistance, oxidative stress and inflammation in high fat-diet/streptozotocin-induced diabetic rat. Life sciences. 2019;216:183-8.
10. Cao H, Polansky MM, Anderson RA. Cinnamon extract and polyphenols affect the expression of tristetraprolin, insulin receptor, and glucose transporter 4 in mouse 3T3-L1 adipocytes. Archives of biochemistry and biophysics. 2007;459(2):214-22.
11. Couturier K, Batandier C, Awada M, Hininger-Favier I, Canini F, Anderson RA, et al. Cinnamon improves insulin sensitivity and alters the body composition in an animal model of the metabolic syndrome. Archives of biochemistry and biophysics. 2010;501(1):158-61.
12. Li W, Qiao J, Lin K, Sun P, Wang Y, Peng Q, et al. Ethyl-acetate fraction from a cinnamon-cortex extract protects pancreatic β-cells from oxidative stress damage. Frontiers in Pharmacology. 2023;14:1111860.
13. Azimi P, Ghiasvand R, Feizi A, Hariri M, Abbasi B. Effects of cinnamon, cardamom, saffron, and ginger consumption on markers of glycemic control, lipid profile, oxidative stress, and inflammation in type 2 diabetes patients. The review of diabetic studies: RDS. 2014;11(3):258.
14. Adisakwattana S, Lerdsuwankij O, Poputtachai U, Minipun A, Suparpprom C. Inhibitory activity of cinnamon bark species and their combination effect with acarbose against intestinal α-glucosidase and pancreatic α-amylase. Plant Foods for Human Nutrition. 2011;66:143-8.
15. Hlebowicz J, Darwiche G, Björgell O, Almér L-O. Effect of cinnamon on postprandial blood glucose, gastric emptying, and satiety in healthy subjects. The American journal of clinical nutrition. 2007;85(6):1552-6.
16. Qi L, Mao H, Lu X, Shi T, Wang J. Cinnamaldehyde promotes the intestinal barrier functions and reshapes gut microbiome in early weaned rats. Frontiers in nutrition. 2021;8:748503.
17. Van Hul M, Geurts L, Plovier H, Druart C, Everard A,



[ DOI: 10.61882/ibj.5073 ]

Ståhlman M, et al. Reduced obesity, diabetes, and steatosis upon cinnamon and grape pomace are associated with changes in gut microbiota and markers of gut barrier. American Journal of Physiology-Endocrinology and Metabolism. 2018;314(4):E334-E52.
18. Syed QA, Rashid Z, Ahmad MH, Shukat R, Ishaq A, Muhammad N, et al. Nutritional and therapeutic properties of fenugreek (Trigonella foenum-graecum): a review. International Journal of Food Properties. 2020;23(1):1777-91.
19. Huseini HF, Fakhrzadeh H, Larijani B, Samani AS. Review of anti-diabetic medicinal plant used in traditional medicine. 2006.
20. Bano D, Tabassum H, Ahmad A, Mabood A, Ahmad IZ. The medicinal significance of the bioactive compounds of Trigonella foenum-graecum: a review. International Journal of Research in Ayurveda & Pharmacy. 2016;7(4):84-91.
21. Snehlata HS, Payal DR. Fenugreek (Trigonella foenum-graecum L.): an overview. 2012.
22. Gong J, Fang K, Dong H, Wang D, Hu M, Lu F. Effect of fenugreek on hyperglycaemia and hyperlipidemia in diabetes and prediabetes: a meta-analysis. Journal of ethnopharmacology. 2016;194:260-8.
23. Shabil M, Bushi G, Bodige PK, Maradi PS, Patra BP, Padhi BK, et al. Effect of fenugreek on hyperglycemia: a systematic review and meta-analysis. Medicina. 2023;59(2):248.
24. Fakhr L, Chehregosha F, Zarezadeh M, Chaboksafar M, Tarighat-Esfanjani A. Effects of fenugreek supplementation on the components of metabolic syndrome: A systematic review and dose-response meta-analysis of randomized clinical trials. Pharmacological Research. 2023;187:106594.
25. Losso JN, Holliday DL, Finley JW, Martin RJ, Rood JC, Yu Y, et al. Fenugreek bread: a treatment for diabetes mellitus. Journal of medicinal food. 2009;12(5):1046-9.
26. Kiss R, Szabó K, Gesztelyi R, Somodi S, Kovács P, Szabó Z, et al. Insulin-sensitizer effects of fenugreek seeds in parallel with changes in plasma MCH levels in healthy volunteers. International journal of molecular sciences. 2018;19(3):771.
27. Sauvaire Y, Petit P, Broca C, Manteghetti M, Baissac Y, Fernandez-Alvarez J, et al. 4-Hydroxyisoleucine: a novel amino acid potentiator of insulin secretion. Diabetes. 1998;47(2):206-10.
28. Tharaheswari M, Jayachandra Reddy N, Kumar R, Varshney K, Kannan M, Sudha Rani S. Trigonelline and diosgenin attenuate ER stress, oxidative stress-mediated damage in pancreas and enhance adipose tissue PPARγ activity in type 2 diabetic rats. Molecular and cellular biochemistry. 2014;396:161-74.
29. Ganeshpurkar A, Diwedi V, Bhardwaj Y. In vitro α-amylase and α-glucosidase inhibitory potential of Trigonella foenum-graecum leaves extract. AYU (An International Quarterly Journal of Research in Ayurveda). 2013;34(1):109-12.
30. Hannan J, Ali L, Rokeya B, Khaleque J, Akhter M, Flatt P, et al. Soluble dietary fibre fraction of Trigonella foenum-graecum (fenugreek) seed improves glucose homeostasis in animal models of type 1 and type 2 diabetes by delaying carbohydrate digestion and absorption, and enhancing insulin action. British Journal of Nutrition. 2007;97(3):514-21.
31. Bruce-Keller AJ, Richard AJ, Fernandez-Kim S-O, Ribnicky DM, Salbaum JM, Newman S, et al. Fenugreek counters the effects of high fat diet on gut microbiota in mice: Links to metabolic benefit. Scientific reports. 2020;10(1):1245.
32. Beiranvand F, Alizadeh M. Plants for remedies of diabetes mellitus in Iran. Plant Biotechnology Persa. 2019;1(1):36-8.
33. Ibrahim M, Rehman K, Razzaq A, Hussain I, Farooq T, Hussain A, et al. Investigations of phytochemical constituents and their pharmacological properties isolated from the genus Urtica: critical review and analysis. Critical Reviews™ in Eukaryotic Gene Expression. 2018;28(1).
34. Bnouham M, Merhfour F-Z, Ziyyat A, Mekhfi H, Aziz M, Legssyer A. Antihyperglycemic activity of the aqueous extract of Urtica dioica. Fitoterapia. 2003;74(7-8):677-81.
35. Kianbakht S, Khalighi-Sigaroodi F, Dabaghian FH. Improved glycemic control in patients with advanced type 2 diabetes mellitus taking Urtica dioica leaf extract: a randomized double-blind placebo-controlled clinical trial. Clin Lab. 2013;59(9-10):1071-6.
36. Khajeh-Mehrizi R, Mozaffari-Khosravi H, Ghadiri-Anari A, Dehghani A. The effect of Urtica dioica extract on glycemic control and insulin resistance indices in patients with type 2 diabetes: a randomized, double-blind clinical trial. Iranian Journal of Diabetes and Obesity. 2014;6(4):149-55.
37. A Tarighat E. [Effect of hydroalcoholic extract of nettle [Urtica Dioica] on glycemic index and insulin resistance index in type 2 diabetic patients]. 2012.
38. Khalili N, Fereydoonzadeh R, Mohtashami R, Mehrzadi S, Heydari M, Huseini HF. Silymarin, olibanum, and nettle, a mixed herbal formulation in the treatment of type II diabetes: A randomized, double-blind, placebo-controlled, clinical trial. Journal of evidence-based complementary & alternative medicine. 2017;22(4):603-8.
39. Salim B, Said G, Kambouche N, Kress S. Identification of phenolic compounds from nettle as new candidate inhibitors of main enzymes responsible on type-II diabetes. Current Drug Discovery Technologies. 2020;17(2):197-202.
40. Shahraki MR, Mirshekari H, Sahraki AR, Shafighi E. Effect of urtica dioica decoction on Serum glucose and lipid profile in stereptozotocin induced diabetic male rats. Zahedan Journal of Research in Medical Sciences. 2013;15(11).
41. Bnouham M, Merhfour FZ, Ziyyat A, Aziz M, Legssyer A, Mekhfi H. Antidiabetic effect of some medicinal plants of Oriental Morocco in neonatal non-insulin-dependent diabetes mellitus rats. Human & experimental toxicology. 2010;29(10):865-71.
42. Obanda DN, Ribnicky D, Yu Y, Stephens J, Cefalu WT. An extract of Urtica dioica L. mitigates obesity induced



[ DOI: 10.61882/ibj.5073 ]

insulin resistance in mice skeletal muscle via protein phosphatase 2A (PP2A). Scientific reports. 2016;6(1):22222.
43. Farzami B, Ahmadvand D, Vardasbi S, Majin F, Khaghani S. Induction of insulin secretion by a component of Urtica dioica leave extract in perifused Islets of Langerhans and its in vivo effects in normal and streptozotocin diabetic rats. Journal of ethnopharmacology. 2003;89(1):47-53.
44. Ahmadi S, Awliaei H, Haidarizadeh M, Rostamzadeh J. The effect of ethanolic extract of urtica dioica leaves on high levels of blood glucose and gene expression of glucose transporter 2 (Glut2) in liver of alloxan-induced diabetic mice. Gene, cell and tissue. 2015;2(3).
45. Gohari A, Noorafshan A, Akmali M, Zamani-Garmsiri F, Seghatoleslam A. Urtica dioica distillate regenerates pancreatic beta cells in streptozotocin-induced diabetic rats. Iranian journal of medical sciences. 2018;43(2):174.
46. Jaiswal V, Lee H-J. Antioxidant activity of Urtica dioica: An important property contributing to multiple biological activities. Antioxidants. 2022;11(12):2494.
47. Fan S, Raychaudhuri S, Page R, Shahinozzaman M, Obanda DN. Metagenomic insights into the effects of Urtica dioica vegetable on the gut microbiota of C57BL/6J obese mice, particularly the composition of Clostridia. The Journal of nutritional biochemistry. 2021;91:108594.
48. Yimer EM, Tuem KB, Karim A, Ur-Rehman N, Anwar F. Nigella sativa L.(black cumin): a promising natural remedy for wide range of illnesses. Evidence-Based Complementary and Alternative Medicine. 2019;2019(1):1528635.
49. Dalli M, Bekkouch O, Azizi S-e, Azghar A, Gseyra N, Kim B. Nigella sativa L. phytochemistry and pharmacological activities: A review (2019–2021). Biomolecules. 2021;12(1):20.
50. Maideen NMP. Antidiabetic activity of nigella sativa (black seeds) and its active constituent (thymoquinone): A review of human and experimental animal studies. Chonnam Medical Journal. 2021;57(3):169.
51. Hosseini M, Mirkarimi S, Amini M, Mohtashami R, Kianbakht S, FALLAH HH. Effects of Nigella sativa L. seed oil in type II diabetic Patients: A randomized, double-blind, placebo-controlled clinical trial. 2013.
52. Najmi A, Nasiruddin M, Khan R, Haque SF. Therapeutic effect of Nigella sativa in patients of poor glycemic control. Asian J Pharm Clin Res. 2012;5(3):224-8.
53. Bamosa AO, Kaatabi H, Lebdaa FM, Elq A-M, Al-Sultanb A. Effect of Nigella sativa seeds on the glycemic control of patients with type 2 diabetes mellitus. Indian J Physiol Pharmacol. 2010;54(4):344-54.
54. Abdelrazek H, Kilany OE, Muhammad MA, Tag HM, Abdelazim AM. Black seed thymoquinone improved insulin secretion, hepatic glycogen storage, and oxidative stress in streptozotocin-induced diabetic male Wistar rats. Oxidative medicine and cellular longevity. 2018;2018.
55. Kanter M, Akpolat M, Aktas C. Protective effects of the volatile oil of Nigella sativa seeds on β-cell damage in streptozotocin-induced diabetic rats: a light and electron microscopic study. Journal of molecular histology. 2009;40:379-85.
56. Tiji S, Bouhrim M, Addi M, Drouet S, Lorenzo JM, Hano C, et al. Linking the phytochemicals and the α-glucosidase and α-amylase enzyme inhibitory effects of Nigella sativa seed extracts. Foods. 2021;10(8):1818.
57. Hadi V, Kheirouri S, Alizadeh M, Khabbazi A, Hosseini H. Effects of Nigella sativa oil extract on inflammatory cytokine response and oxidative stress status in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled clinical trial. Avicenna journal of phytomedicine. 2016;6(1):34.
58. Kanter M, Meral I, Yener Z, Ozbek H, Demir H. Partial regeneration/proliferation of the β-cells in the Islets of Langerhans by Nigella sativa L. in streptozotocin-induced diabetic rats. The Tohoku journal of experimental medicine. 2003;201(4):213-9.
59. Meddah B, Ducroc R, Faouzi MEA, Eto B, Mahraoui L, Benhaddou-Andaloussi A, et al. Nigella sativa inhibits intestinal glucose absorption and improves glucose tolerance in rats. Journal of ethnopharmacology. 2009;121(3):419-24.
60. Benhaddou-Andaloussi A, Martineau LC, Spoor D, Vuong T, Leduc C, Joly E, et al. Antidiabetic activity of Nigella sativa. Seed extract in cultured pancreatic β-cells, skeletal muscle cells, and adipocytes. Pharmaceutical biology. 2008;46(1-2):96-104.
61. Dong J, Liang Q, Niu Y, Jiang S, Zhou L, Wang J, et al. Effects of Nigella sativa seed polysaccharides on type 2 diabetic mice and gut microbiota. International Journal of Biological Macromolecules. 2020;159:725-38.
62. Hussain AI, Rathore HA, Sattar MZ, Chatha SA, Sarker SD, Gilani AH. Citrullus colocynthis (L.) Schrad (bitter apple fruit): A review of its phytochemistry, pharmacology, traditional uses and nutritional potential. Journal of ethnopharmacology. 2014;155(1):54-66.
63. Khanum H, Ishtiaq M, Maqbool M, Hussain I, Bhatti KH, Mazhar MW, et al. Evaluating the Conservation Value and Medicinal Potential of Wild Herbaceous Flora in the Sanghar Mountains of District Bhimber, AJK, Pakistan. Ethnobotany Research and Applications. 2024;27:1-41.
64. Bernard SA, Olayinka OA. Search for a novel antioxidant, anti-inflammatory/analgesic or anti-proliferative drug: Cucurbitacins hold the ace. Journal of Medicinal Plants Research. 2010;4(25):2821-6.
65. Abdel-Hassan IA, Abdel-Barry JA, Mohammeda ST. The hypoglycaemic and antihyperglycaemic effect of Citrullus colocynthis fruit aqueous extract in normal and alloxan diabetic rabbits. Journal of ethnopharmacology. 2000;71(1-2):325-30.
66. Huseini HF, Darvishzadeh F, Heshmat R, Jafariazar Z, Raza M, Larijani B. The clinical investigation of Citrullus colocynthis (L.) schrad fruit in treatment of Type II diabetic patients: a randomized, double blind, placebo-controlled clinical trial. Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives. 2009;23(8):1186-9.
67. Benariba N, Djaziri R, Hupkens E, Louchami K, Malaisse WJ, Sener A. Insulinotropic action of Citrullus



[ DOI: 10.61882/ibj.5073 ]

colocynthis seed extracts in rat pancreatic islets. Molecular Medicine Reports. 2013;7(1):233-6.
68. Alblooshi M, Devarajan AR, Singh BP, Ramakrishnan P, Mostafa H, Kamal H, et al. Multifunctional bioactive properties of hydrolysates from colocynth (Citrullus colocynthis) seeds derived proteins: Characterization and biological properties. Plant Physiology and Biochemistry. 2023;194:326-34.
69. Fallah Huseini H, Zaree A, Heshmat R, Larijani B, Fakhrzadeh H, Rezaii Sharifabadi R, et al. The effect of Citrullus colocynthis (L.) Schrad. fruit on oxidative stress parameters in type II diabetic patients. Journal of Medicinal Plants. 2006;5(17):55-60.
70. Hussein MA, El-Gizawy HA-E, Gobba NAEK, Mosaad YO. Synthesis of cinnamyl and caffeoyl derivatives of Cucurbitacin-Eglycoside Isolated from Citrullus colocynthis fruits and their structures antioxidant and anti-inflammatory activities relationship. Current Pharmaceutical Biotechnology. 2017;18(8):677-93.
71. Fallah Huseini H, Andalib S, Jasemi E, Khalighi-Sigaroodi F, Momtaz S, Mohammadi Savadroodbari R, et al. Protective effect of Citrullus colocynthis (L.) Schard. fruit extract on high glucose-induced neurotoxicity in PC-12 cells. Journal of Medicinal Plants. 2021;20(80):60-8.
72. Wei L, Ji L, Miao Y, Han X, Li Y, Wang Z, et al. Constipation in DM are associated with both poor glycemic control and diabetic complications: Current status and future directions. Biomedicine & Pharmacotherapy. 2023;165:115202.
73. Fallah Huseini H, Hemati A, Alavian S. A review of herbal medicine: Silybum marianum. Journal of Medicinal Plants. 2004;3(11):14-24.
74. Zhang X, Liu M, Wang Z, Wang P, Kong L, Wu J, et al. A review of the botany, phytochemistry, pharmacology, synthetic biology and comprehensive utilization of Silybum marianum. Frontiers in Pharmacology. 2024;15:1417655.
75. Xu F, Han C, Li Y, Zheng M, Xi X, Hu C, et al. The chemical constituents and pharmacological actions of silybum marianum. Current Nutrition & Food Science. 2019;15(5):430-40.
76. Stolf AM, Cardoso CC, Acco A. Effects of silymarin on diabetes mellitus complications: a review. Phytotherapy research. 2017;31(3):366-74.
77. Huseini HF, Larijani B, Heshmat R, Fakhrzadeh H, Radjabipour B, Toliat T, et al. The efficacy of Silybum marianum (L.) Gaertn.(silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives. 2006;20(12):1036-9.
78. Mohammadi S, Afkhami Ardacani M, Salami M, Bolurani S. Effects of silymarin on insulin resistance and blood lipid profile in first-degree relatives of type 2 diabetic patients. Journal of medicinal plants. 2013;12(46):170-6.
79. H Fallah H. < The> effects of silybum marianum [L.] gaertn. seed extract on glycemic control in type II diabetic patient's candidate for insulin therapy visiting endocrinology clinic in baqiyatallah hospital in the years of 2006. 2008.
80. Meng R, Mahadevan J, Oseid E, Vallerie S, Robertson RP. Silymarin activates c-AMP phosphodiesterase and stimulates insulin secretion in a glucose-dependent manner in HIT-T15 cells. Antioxidants. 2016;5(4):47.
81. Qin N, Hu X, Li S, Wang J, Li Z, Li D, et al. Hypoglycemic effect of silychristin A from Silybum marianum fruit via protecting pancreatic islet β cells from oxidative damage and inhibiting α-glucosidase activity in vitro and in rats with type 1 diabetes. Journal of functional foods. 2017;38:168-79.
82. Soto C, Raya L, Juárez J, Pérez J, González I. Effect of Silymarin in Pdx-1 expression and the proliferation of pancreatic β-cells in a pancreatectomy model.
83. Fallah Huseini H, Asghari B, Asgarpanah J, Eghbali Zarch T, Babai Zarch A. Investigation of α-Amylase and α-Glucosidases Inhibitory Effects of Silybum marianum (L. Gaertn) Seed Extracts In Vitro. Journal of Medicinal
84. Gargari BP, Mobasseri M, Valizadeh H, Asghari-Jafarabadi M. Effects of Silybum marianum (L.) Gaertn.(silymarin) extract supplementation on antioxidant status and hs-CRP in patients with type 2 diabetes mellitus: a randomized, triple-blind, placebo-controlled clinical trial. Phytomedicine. 2015;22(2):290-
85. Xu F, Yang J, Negishi H, Sun Y, Li D, Zhang X, et al. Silibinin decreases hepatic glucose production through the activation of gut–brain–liver axis in diabetic rats.
86. Xu S, Jiang X, Jia X, Jiang X, Che L, Lin Y, et al. Silymarin modulates microbiota in the gut to improve the health of sow from late gestation to lactation. Animals.
87. Khodaie L, Sadeghpoor O. Ginger from ancient times to the new outlook. Jundishapur journal of natural pharmaceutical products. 2015;10(1):e18402.
88. Liu Y, Liu J, Zhang Y. Research progress on chemical constituents of Zingiber officinale Roscoe. BioMed research international. 2019;2019(1):5370823.
89. Shidfar F, Rajab A, Rahideh T, Khandouzi N, Hosseini S, Shidfar S. The effect of ginger (Zingiber officinale) on glycemic markers in patients with type 2 diabetes. Journal of complementary and integrative medicine. 2015;12(2):165-70.
90. Nam YH, Hong BN, Rodriguez I, Park MS, Jeong SY, Lee Y-G, et al. Steamed ginger may enhance insulin secretion through KATP channel closure in pancreatic β-cells potentially by increasing 1-dehydro-6-gingerdione content. Nutrients. 2020;12(2):324.
91. Mozaffari-Khosravi H, Talaei B, Jalali B-A, Najarzadeh A, Mozayan MR. The effect of ginger powder supplementation on insulin resistance and glycemic indices in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Complementary therapies in medicine. 2014;22(1):9-16.
92. Samad MB, Mohsin MNAB, Razu BA, Hossain MT, Mahzabeen S, Unnoor N, et al. [6]-Gingerol, from Zingiber officinale, potentiates GLP-1 mediated glucose-stimulated insulin secretion pathway in pancreatic β-cells and increases RAB8/RAB10-regulated membrane presentation of GLUT4 transporters in skeletal muscle to



[ DOI: 10.61882/ibj.5073 ]

improve hyperglycemia in Lepr db/db type 2 diabetic mice. BMC complementary and alternative medicine. 2017;17:1-13.
93. Venkateswaran M, Jayabal S, Hemaiswarya S, Murugesan S, Enkateswara S, Doble M, et al. Polyphenol-rich Indian ginger cultivars ameliorate GLUT4 activity in C2C12 cells, inhibit diabetes-related enzymes and LPS-induced inflammation: An in vitro study. Journal of Food Biochemistry. 2021;45(2):e13600.
94. Priya Rani M, Padmakumari K, Sankarikutty B, Lijo Cherian O, Nisha V, Raghu K. Inhibitory potential of ginger extracts against enzymes linked to type 2 diabetes, inflammation and induced oxidative stress. International Journal of Food Sciences and Nutrition. 2011;62(2):106-10.
95. Al Hroob AM, Abukhalil MH, Alghonmeen RD, Mahmoud AM. Ginger alleviates hyperglycemia-induced oxidative stress, inflammation and apoptosis and protects rats against diabetic nephropathy. Biomedicine & Pharmacotherapy. 2018;106:381-9.
96. Wang X, Zhang D, Jiang H, Zhang S, Pang X, Gao S, et al. Gut microbiota variation with short-term intake of ginger juice on human health. Frontiers in Microbiology. 2021;11:576061.
97. Wang R, Santos JM, Dufour JM, Stephens ER, Miranda JM, Washburn RL, et al. Ginger root extract improves GI health in diabetic rats by improving intestinal integrity and mitochondrial function. Nutrients. 2022;14(20):4384.
98. Nojavan F, Danesh A. The Review of attributes of pomegranate in view of Iranian traditional medicine and Modern medicine. Journal of Islamic and Iranian Traditional Medicine. 2017;8(1):35-45.
99. Vučić V, Grabež M, Trchounian A, Arsić A. Composition and potential health benefits of pomegranate: a review. Current pharmaceutical design. 2019;25(16):1817-27.
100. Banihani S, Swedan S, Alguraan Z. Pomegranate and type 2 diabetes. Nutrition research. 2013;33(5):341-8.
101. 101. Jyothsna D. The Study of Effect of Pomegranate Juice on Type 2 Diabetes Mellietus. IOSR Journal of Dental and Medical Sciences. 2017;16(4):28-30.
102. Fuster-Muñoz E, Roche E, Funes L, Martínez-Peinado P, Sempere J, Vicente-Salar N. Effects of pomegranate juice in circulating parameters, cytokines, and oxidative stress markers in endurance-based athletes: A randomized controlled trial. Nutrition. 2016;32(5):539-45.
103. Banihani S, Makahleh S, El-Akawi Z, Al-Fashtaki R, Khabour O, Gharibeh M, et al. Fresh pomegranate juice ameliorates insulin resistance, enhances β-cell function, and decreases fasting serum glucose in type 2 diabetic patients. Nutrition research. 2014;34(10):862-7.
104. Xu J, Zhao Y, Aisa HA. Anti-inflammatory effect of pomegranate flower in lipopolysaccharide (LPS)-stimulated RAW264. 7 macrophages. Pharmaceutical Biology. 2017;55(1):2095-101.
105. KÜÇÜKBAY FZ, TEKİN Z. Evaluation of phytochemical contents and antioxidant activity of pomegranate flower. Journal of the Turkish Chemical Society Section A: Chemistry. 2020;7(1):37-42.
106. Li Y, Wen S, Kota BP, Peng G, Li GQ, Yamahara J, et al. Punica granatum flower extract, a potent α-glucosidase inhibitor, improves postprandial hyperglycemia in Zucker diabetic fatty rats. Journal of ethnopharmacology. 2005;99(2):239-44.
107. Tang D, Liu L, Ajiakber D, Ye J, Xu J, Xin X, et al. Anti-diabetic effect of Punica granatum flower polyphenols extract in type 2 diabetic rats: Activation of Akt/GSK-3β and inhibition of IRE1α-XBP1 pathways. Frontiers in endocrinology. 2018;9:586.
108. Li Z, Summanen PH, Komoriya T, Henning SM, Lee R-P, Carlson E, et al. Pomegranate ellagitannins stimulate growth of gut bacteria in vitro: Implications for prebiotic and metabolic effects. Anaerobe. 2015;34:164-8.
109. Khare R, Upmanyu N, Shukla T, Jain V, Jha M. Compendium of Salvia officinalis: an Overview. Current Traditional Medicine. 2020;6(4):300-11.
110. Ghorbani A, Esmaeilizadeh M. Pharmacological properties of Salvia officinalis and its components. Journal of traditional and complementary medicine. 2017;7(4):433-40.
111. Abdollahi A, Adelibahram F, Ghassab-Abdollahi N, Araj-Khodaei M, Parsian Z, Mirghafourvand M. The effect of Salvia officinalis on blood glycemic indexes and blood lipid profile in diabetic patients: a systematic review and meta-analysis. Journal of Complementary and Integrative Medicine. 2023;20(3):521-9.
112. Eidi M, Eidi A, Zamanizadeh H. Effect of Salvia officinalis L. leaves on serum glucose and insulin in healthy and streptozotocin-induced diabetic rats. Journal of ethnopharmacology. 2005;100(3):310-3.
113. Kianbakht S, Nabati F, Abasi B. Salvia officinalis (Sage) leaf extract as add-on to statin therapy in hypercholesterolemic type 2 diabetic patients: a randomized clinical trial. International journal of molecular and cellular medicine. 2016;5(3):141.
114. Mahdi S, Azzi R, Lahfa FB. Evaluation of in vitro α-amylase and α-glucosidase inhibitory potential and hemolytic effect of phenolic enriched fractions of the aerial part of Salvia officinalis L. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020;14(4):689-94.
115. Lima CF, Azevedo MF, Araujo R, Fernandes-Ferreira M, Pereira-Wilson C. Metformin-like effect of Salvia officinalis (common sage): is it useful in diabetes prevention? British journal of nutrition. 2006;96(2):326-33.
116. Kolac UK, Ustuner MC, Tekin N, Ustuner D, Colak E, Entok E. The anti-inflammatory and antioxidant effects of Salvia officinalis on lipopolysaccharide-induced inflammation in rats. Journal of medicinal food. 2017;20(12):1193-200.
117. Khedher MRB, Hammami M, Arch JR, Hislop DC, Eze D, Wargent ET, et al. Preventive effects of Salvia officinalis leaf extract on insulin resistance and inflammation in a model of high fat diet-induced obesity in mice that responds to rosiglitazone. PeerJ. 2018;6:e4166.
118. Hussein EE, El Basuini MF, Ashry AM, Habiba MM,



[ DOI: 10.61882/ibj.5073 ]

Teiba II, El-Rayes TK, et al. Effect of dietary sage (Salvia officinalis L.) on the growth performance, feed efficacy, blood indices, non-specific immunity, and intestinal microbiota of European sea bass (Dicentrarchus labrax). Aquaculture Reports. 2023;28:101460.
119. Nickavar B, Amin G. Anthocyanins from Vaccinium arctostaphylos berries. Pharmaceutical Biology. 2004;42(4-5):289-91.
120. Kianbakht S, Abasi B, Dabaghian FH. Anti-hyperglycemic effect of Vaccinium arctostaphylos in type 2 diabetic patients: A randomized controlled trial. Forschende Komplementärmedizin/Research in Complementary Medicine. 2013;20(1):17-22.
121. Mohtashami R, Huseini HF, Nabati F, Hajiaghaee R, Kianbakht S. Effects of standardized hydro-alcoholic extract of Vaccinium arctostaphylos leaf on hypertension and biochemical parameters in hypertensive hyperlipidemic type 2 diabetic patients: a randomized, double-blind and placebo-controlled clinical trial. Avicenna journal of phytomedicine. 2019;9(1):44.
122. Mirfeizi M, Mehdizadeh Tourzani Z, Mirfeizi SZ, Asghari Jafarabadi M, Rezvani HR, Afzali M. Controlling type 2 diabetes mellitus with herbal medicines: A triple-blind randomized clinical trial of efficacy and safety: 使用草药来控制 2 型糖尿病: 一项验证有效性与安全性的三盲随机临床试验. Journal of diabetes. 2016;8(5):647-56.
123. Saliani N, Kouhsari SM, Izad M. The potential hepatoprotective effect of Vaccinium arctostaphylos L. fruit extract in diabetic rat. Cell Journal (Yakhteh). 2023;25(10):717.
124. Bharti SK, Krishnan S, Kumar A, Kumar A. Antidiabetic phytoconstituents and their mode of action on metabolic pathways. Therapeutic Advances in Endocrinology and metabolism. 2018;9(3):81-100.
125. Leto D, Saltiel AR. Regulation of glucose transport by insulin: traffic control of GLUT4. Nature reviews Molecular cell biology. 2012;13(6):383-96.
126. Soltani R, Hakimi M, Asgary S, Ghanadian SM, Keshvari M, Sarrafzadegan N. Evaluation of the effects of Vaccinium arctostaphylos L. Fruit extract on serum lipids and hs-CRP levels and oxidative stress in adult patients with hyperlipidemia: A randomized, double-blind, placebo-controlled clinical trial. Evidence-Based Complementary and Alternative Medicine. 2014;2014(1):217451.
127. 127. Barut B, Barut EN, Engin S, Arzu Ö, Sezen FS. Investigation of the antioxidant, α-glucosidase inhibitory, anti-inflammatory, and DNA protective properties of Vaccinium arctostaphylos L. Turkish Journal of Pharmaceutical Sciences. 2019;16(2):175.
128. 128. Mukherjee S, Karati D. Exploring the phytochemistry, pharmacognostic properties, and pharmacological activities of medically important plant Momordica charantia. Pharmacological Research-Modern Chinese Medicine. 2023;6:100226.
129. 129. Joseph B, Jini D. Antidiabetic effects of Momordica charantia (bitter melon) and its medicinal potency. Asian pacific journal of tropical disease. 2013;3(2):93-102.
130. 130. Xu X, Shan B, Liao C-H, Xie J-H, Wen P-W, Shi J-Y. Anti-diabetic properties of Momordica charantia L. polysaccharide in alloxan-induced diabetic mice. International journal of biological macromolecules. 2015;81:538-43.
131. Cortez-Navarrete M, Martínez-Abundis E, Pérez-Rubio KG, González-Ortiz M, Méndez-del Villar M. Momordica charantia administration improves insulin secretion in type 2 diabetes mellitus. Journal of medicinal food. 2018;21(7):672-7.
132. Shih CC, Shlau MT, Lin CH, Wu JB. Momordica charantia ameliorates insulin resistance and dyslipidemia with altered hepatic glucose production and fatty acid synthesis and AMPK phosphorylation in high-fat-fed mice. Phytotherapy Research. 2014;28(3):363-71.
133. Lo H-Y, Ho T-Y, Li C-C, Chen J-C, Liu J-J, Hsiang C-Y. A novel insulin receptor-binding protein from Momordica charantia enhances glucose uptake and glucose clearance in vitro and in vivo through triggering insulin receptor signaling pathway. Journal of agricultural and food chemistry. 2014;62(36):8952-61.
134. Zhang C, Chen H, Bai W. Characterization of Momordica charantia L. polysaccharide and its protective effect on pancreatic cells injury in STZ-induced diabetic mice. International journal of biological macromolecules. 2018;115:45-52.
135. Tan H-F, Gan C-Y. Polysaccharide with antioxidant, α-amylase inhibitory and ACE inhibitory activities from Momordica charantia. International journal of biological macromolecules. 2016;85:487-96.
136. Chen F, Huang G, Yang Z, Hou Y. Antioxidant activity of Momordica charantia polysaccharide and its derivatives. International journal of biological macromolecules. 2019;138:673-80.
137. Wen J-J, Li M-Z, Gao H, Hu J-L, Nie Q-X, Chen H-H, et al. Polysaccharides from fermented Momordica charantia L. with Lactobacillus plantarum NCU116 ameliorate metabolic disorders and gut microbiota change in obese rats. Food & Function. 2021;12(6):2617-30.
138. Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, et al. Pathophysiology of type 2 diabetes mellitus. International journal of molecular sciences. 2020;21(17):6275.
139. Tavakolizadeh M, Peyrovi S, Ghasemi-Moghaddam H, Bahadori A, Mohkami Z, Sotoudeh M, et al. Clinical efficacy and safety of okra (Abelmoschus esculentus (L.) Moench) in type 2 diabetic patients: a randomized, double-blind, placebo-controlled, clinical trial. Acta Diabetologica. 2023;60(12):1685-95.
140. Fallah Huseini H, Yaghoobi M, Fallahi F, Boroumand F, Ezzati MH, Tabatabaei SM, et al. Topical administration of teucrium polium on diabetic foot ulcers accelerates healing: a placebo-controlled randomized clinical study. The International Journal of Lower Extremity Wounds. 2021:15347346211048371.
141. Oghbaei H, Fattahi A, Hamidian G, Sadigh-Eteghad S, Ziaee M, Mahmoudi J. A closer look at the role of insulin for the regulation of male reproductive function. General and comparative endocrinology. 2021;300:113643.



[ DOI: 10.61882/ibj.5073 ]

142. Mahgoub MO, Ali II, Adeghate JO, Tekes K, Kalász H, Adeghate EA. An update on the molecular and cellular basis of pharmacotherapy in type 2 diabetes mellitus. International journal of molecular sciences. 2023;24(11):9328.
143. Gong L, Feng D, Wang T, Ren Y, Liu Y, Wang J. Inhibitors of α-amylase and α-glucosidase: Potential linkage for whole cereal foods on prevention of hyperglycemia. Food science & nutrition. 2020;8(12):6320-37.
144. Arabshomali A, Bazzazzadehgan S, Mahdi F, Shariat-Madar Z. Potential benefits of antioxidant phytochemicals in type 2 diabetes. Molecules. 2023;28(20):7209.
145. Ceriello A, Testa R. Antioxidant anti-inflammatory treatment in type 2 diabetes. Diabetes care. 2009;32(Suppl 2):S232.
146. Mulvihill EE, Drucker DJ. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocrine reviews. 2014;35(6):992-1019.
147. Iatcu CO, Steen A, Covasa M. Gut microbiota and complications of type-2 diabetes. Nutrients. 2021;14(1):166.
148. 148. Festi D, Schiumerini R, Eusebi LH, Marasco G, Taddia M, Colecchia A. Gut microbiota and metabolic syndrome. World journal of gastroenterology: WJG. 2014;20(43):16079.
149. Mohanty D, Misra S, Mohapatra S, Sahu PS. Prebiotics and synbiotics: Recent concepts in nutrition. Food bioscience. 2018;26:152-60.
150. Lee CB, Chae SU, Jo SJ, Jerng UM, Bae SK. The relationship between the gut microbiome and metformin as a key for treating type 2 diabetes mellitus. International journal of molecular sciences. 2021;22(7):3566.



[ DOI: 10.61882/ibj.5073 ]